MS

Most patients with appendicitis can have antibiotics as their first treatment, rather than appendectomy

Monday, October 25, 2021 - 4:00pm

CODA is the largest randomized clinical trial to explore whether antibiotic treatment is as good as appendectomy in treating appendicitis.

Key Points: 
  • CODA is the largest randomized clinical trial to explore whether antibiotic treatment is as good as appendectomy in treating appendicitis.
  • The study was conducted at 25 U.S. medical centers in 1,552 adults with appendicitis who were randomly assigned to receive either antibiotics or appendectomy.
  • Among the study patients who initially received nonoperative treatment, the proportion who eventually underwent an appendectomy increased over time.
  • To help patients make treatment decisions regarding their appendicitis, CODA investigators developed an online decision-making tool, available at http://www.appyornot.org/ (.

The American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award

Monday, October 25, 2021 - 2:00pm

ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.

Key Points: 
  • ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.
  • "Flatiron Health is honored to partner with ACS to leverage Flatiron's EHR-derived real-world data to advance research toward better and more equitable cancer treatments and outcomes," said Rebecca Miksad, MD, MPH, senior medical director at Flatiron Health.
  • Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow.
  • Flatiron.com @FlatironHealth
    The American Cancer Society is on a mission to free the world from cancer.

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Monday, October 25, 2021 - 1:00pm

I couldnt imagine a more exciting time and opportunity to join Flare, said Ms. Karydas.

Key Points: 
  • I couldnt imagine a more exciting time and opportunity to join Flare, said Ms. Karydas.
  • Daphne Karydas brings to Flare over 20 years of financial and operations experience in the biopharmaceutical industry, most recently as Chief Financial Officer for Syndax Pharmaceuticals (Nasdaq: SNDX.)
  • Ms. Karydas received a BA and MS in chemical engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
  • Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update

Monday, October 25, 2021 - 12:00pm

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

American Oncology Network In-House Specialty Pharmacy Earns Third Accreditation

Monday, October 25, 2021 - 12:00pm

Fort Myers, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- The American Oncology Network, LLC (AON) in-house specialty pharmacy is pleased to announce their recent accreditations by the National Association of Boards of Pharmacy (NABP) for specialty pharmacy practice and for digital pharmacy practice.

Key Points: 
  • Fort Myers, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- The American Oncology Network, LLC (AON) in-house specialty pharmacy is pleased to announce their recent accreditations by the National Association of Boards of Pharmacy (NABP) for specialty pharmacy practice and for digital pharmacy practice.
  • NABPs Specialty Pharmacy Accreditation signifies to patients, payers, and providers that the pharmacy organization is recognized for providing an advanced level of pharmacy services and disease management for patients taking medications that require special handling, storage and distribution requirements.
  • NABPs Digital Pharmacy Accreditation signifies the pharmacy organization is recognized for its commitment to quality health care and safe pharmacy practices over the internet.
  • American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology.

Mutual of America Financial Group Names Tara Favors as EVP and Chief Human Resources Officer

Friday, October 22, 2021 - 4:26pm

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- Mutual of America Financial Group , which specializes in providing retirement and investment services to organizations and individuals, is pleased to introduce Tara Favors as Executive Vice President and Chief Human Resources Officer.

Key Points: 
  • NEW YORK, Oct. 22, 2021 /PRNewswire/ -- Mutual of America Financial Group , which specializes in providing retirement and investment services to organizations and individuals, is pleased to introduce Tara Favors as Executive Vice President and Chief Human Resources Officer.
  • In this role, Favors will be responsible for all aspects of human resources strategy for the company, which has more than 1,100 employees nationwide.
  • Favors has more than 20 years of experience in human resources leadership roles in financial services and other sectors.
  • Favors earned a BA in Psychology from Syracuse University and an MS in Human Resources from The New School University.

Washington State's Veterinary Association Announces Annual Award Winners

Thursday, October 21, 2021 - 10:42pm

REDMOND, Wash., Oct. 21, 2021 /PRNewswire/ --The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference Oct. 1 Oct 3 in a virtual, online platform.

Key Points: 
  • REDMOND, Wash., Oct. 21, 2021 /PRNewswire/ --The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference Oct. 1 Oct 3 in a virtual, online platform.
  • Veterinarians and veterinary staff were honored at WSVMA's award ceremonies on Friday, Oct. 1.
  • The award is presented in recognition of an outstanding career in veterinary medicine and contributions made to their practice, stakeholders, and other service directly benefitting their community.
  • Visit the WSVMA Web site, www.wsvma.org , to learn more about the association, veterinary medicine, and animal care.

Integrity Applications Announces the Appointment of Paul V. Goode, PhD, as President and Chief Operating Officer

Thursday, October 21, 2021 - 3:00pm

Paul has served as a member of Integritys Board of Directors since December 17, 2020.

Key Points: 
  • Paul has served as a member of Integritys Board of Directors since December 17, 2020.
  • Concurrent with his new appointment, Mr. Goode will be stepping down from the Board.
  • Paul is a highly accomplished medical device professional with extensive experience in all areas of operations and product development, from initial concept to global commercialization.
  • Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.

Mapi Pharma Signs Agreement with Gaelan Medical Trade LLC to Exclusively Market and Distribute Mapi Products in UAE

Thursday, October 21, 2021 - 1:30pm

This partnership is an important consequence of the Abraham Accords Peace Agreement signed recently between Israel and the UAE.

Key Points: 
  • This partnership is an important consequence of the Abraham Accords Peace Agreement signed recently between Israel and the UAE.
  • Gaelan has extensive knowledge and experience in specialty generic products and has a strong reach into all the major clinical institutions in the UAE, said Ghassan Aboud, Chairman, Ghassan Aboud Group.
  • Gaelan Medical with its experienced management team, caters to diverse healthcare needs including, pharmaceuticals, medical consumables, medical equipment, and beauty products.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint

Thursday, October 21, 2021 - 12:30pm

The studys primary endpoint is speech perception, a measure of sound clarity and understanding speech.

Key Points: 
  • The studys primary endpoint is speech perception, a measure of sound clarity and understanding speech.
  • The U.S. Food and Drug Administration (FDA), in a recent Type-C meeting with the Company, agreed that speech perception is an acceptable primary efficacy endpoint.
  • A variety of other listening tests, including multiple measures of speech perception and pure tone thresholds, will also be assessed.
  • In two previous clinical studies, the Company observed statistically significant improvements in speech perception scores in individuals with acquired sensorineural hearing loss.